Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Waiting on FDA clearance for the Symphony IL-6 test? Every line in Bluejay Diagnostics’ disclosures tells part of that story. This page gathers the company’s complete regulatory trail so you can move straight to the data that matters—cash runway, clinical-trial results, and insider conviction—without digging through EDGAR on your own.
Start with the Bluejay Diagnostics annual report 10-K simplified to see long-term risk factors around point-of-care diagnostics. Need quarterly updates on R&D spend? The Bluejay Diagnostics quarterly earnings report 10-Q filing links revenue, burn rate, and Symphony development milestones. Material study readouts or FDA feedback drop in 8-Ks—scroll down for Bluejay Diagnostics 8-K material events explained. Curious whether management is buying shares ahead of catalysts? Check Bluejay Diagnostics insider trading Form 4 transactions and our Bluejay Diagnostics Form 4 insider transactions real-time alerts. Even the proxy offers insight: the Bluejay Diagnostics proxy statement executive compensation reveals how leadership is incentivized to hit regulatory targets.
Stock Titan’s engine turns dense text into insight. Our AI-powered summaries answer the questions you actually ask—“What FDA milestones are disclosed?” or “How much cash remains for clinical studies?”—making understanding Bluejay Diagnostics SEC documents with AI effortless. You’ll find concise Bluejay Diagnostics earnings report filing analysis, instant flags on Bluejay Diagnostics executive stock transactions Form 4, and real-time push updates across every form type. With Bluejay Diagnostics SEC filings explained simply, you save hours and make better-informed decisions before the market reacts.
Bluejay Diagnostics, Inc. furnished a Current Report stating that, following its quarterly report for the fiscal quarter ended June 30, 2025, the company issued a press release providing a 2025 second quarter business and corporate update.
The press release is furnished as Exhibit 99.1 and the cover page interactive data file is included as Exhibit 104. The filing specifies the information is being furnished and is not "filed" under the Exchange Act and will not be incorporated by reference into other filings unless identified. The report was signed by Neil Dey, President and Chief Executive Officer.
FAQ
What is the current stock price of Bluejay Diagnostics (BJDX)?
What is the market cap of Bluejay Diagnostics (BJDX)?
